Quantcast

Latest Interventional cardiology Stories

2014-09-14 12:20:52

- Abbott's Absorb Bioresorbable Vascular Scaffold (BVS) is a revolutionary medical device, used in the heart, that functions like a stent but dissolves over time WASHINGTON, Sept. 14, 2014 /PRNewswire/ -- Abbott announced today positive one-year clinical results from ABSORB II, the world's first prospective, randomized, controlled trial comparing the safety and effectiveness of the dissolving Absorb heart device to Abbott's market-leading metallic XIENCE family of DES. The trial,...

2014-09-12 08:25:54

Olson Brings 25 Years of Non-Profit and Medical Industry Experience WASHINGTON, Sept. 12, 2014 /PRNewswire/ -- The Society for Cardiovascular Angiography and Interventions (SCAI) has named Lisa Olson, PhD, as its new executive director. Olson brings deep experience and expertise in the cardiovascular field and a vision for continuing to advance SCAI's mission. Olson joins SCAI from consulting firm aha Group, which she launched in 1999 to provide strategic marketing, market...

2014-09-12 08:24:55

From 1969 to September 5, 2014, 1,413 artificial hearts of 13 different designs have been implanted in heart failure patients. Here's an update on the state of this life-saving technology. TUCSON, Ariz., Sept. 12, 2014 /PRNewswire/ -- Cardiovascular disease, which includes heart failure, is the number one cause of death, killing more people worldwide than all cancers combined. http://photos.prnewswire.com/prnvar/20140911/145568 The need for donor hearts is growing as heart disease continues...

2014-09-10 08:32:05

Data Will Focus on Areas of Significant Unmet Patient Need, Including Coronary Artery Disease and Aortic Valve Disease MARLBOROUGH, Mass., Sept. 10, 2014 /PRNewswire/ -- Beginning Saturday, Boston Scientific Corporation (NYSE: BSX) will present data that reinforce the company's commitment to advancing science for life and to developing innovative therapies in interventional cardiology. The company will share results from more than a dozen clinical studies at the 26th Transcatheter...

2014-09-09 16:26:44

PLEASANTON, Calif., Sept. 9, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that it has begun to enroll patients in the HeartMate III(TM) U.S. clinical trial. "We are excited to continue our recent pipeline progress with the start of the U.S. clinical trial for HeartMate III," said Gary F. Burbach, President and Chief Executive Officer....

2014-09-09 12:29:07

STASIS Clinical Study Begins in Europe NEWTOWN, Pa., Sept. 9, 2014 /PRNewswire/ -- Micro Interventional Devices, Inc. (MID) reports the first successful clinical case using its Permaseal Cardiac Access and Closure technology. This new technology simplifies minimally invasive aortic valve replacement procedures. The patient is the first to be enrolled in the Secure Transapical Access and Closure Study (STASIS) being conducted in Europe. The first STASIS case was performed by Dr....

2014-09-07 08:20:28

MarketOptimizer.org adds new report "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. DALLAS, Sept. 7, 2014 /PRNewswire-iReach/ -- New PharmaPoint Drug Evaluation report, "Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023". The current ACS market - primarily comprised of...

2014-09-04 23:05:46

iData Research transcatheter cardiovascular therapeutics global survey results revealed dramatic differences between geographical regions in drug-coated balloon usage trends. Vancouver, BC (PRWEB) September 04, 2014 According to a recent transcatheter cardiovascular therapeutics global survey conducted by iData Research (http://www.idataresearch.com), the leading global authority in medical device market research, the majority of interventional cardiologists see limited use of drug-coated...

2014-09-04 23:02:54

Memorial Regional Hospital is only one of two Ventricular Assisted Device programs now serving the South Florida community. Hollywood, Fl (PRWEB) September 04, 2014 Memorial Regional Hospital, a leading provider of adult cardiac services in Florida, recently earned The Joint Commission’s Gold Seal of Approval for its ventricular assist device (VAD) destination therapy program, offered through its Memorial Cardiac and Vascular Institute. Memorial Regional Hospital is the first hospital...

2014-08-29 16:23:53

PLEASANTON, Calif., Aug. 29, 2014 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today it will be participating in the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, September 10. Gary F. Burbach, President and Chief Executive Officer, will provide an update on the company, beginning at 12:55 p.m., Eastern Daylight Time (9:55 a.m., Pacific...


Latest Interventional cardiology Reference Libraries

Coronary Angiography
2013-07-29 11:05:01

A coronary angiography, also known as a coronary catheterization, is a procedure that gives both visual and tactical access to coronary circulation and blood filled chambers of the heart for both diagnostic and interventional purposes. It is one of many diagnostic tests used in cardiology. More specifically, coronary catheterization recognizes occlusion, stenosis, thrombosis or aneurismal enlargement of the walls of the coronary arteries; heart chamber size; heart muscle contraction...

More Articles (1 articles) »
Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'